Background
Phase III, open-label, 3-arm RCT (GHSG HD15). 2,182 patients with advanced-stage classical Hodgkin lymphoma (GHSG stages IIB with risk factors, III, IV). Designed to reduce chemotherapy intensity in advanced HL by comparing 8×BEACOPP escalated (standard at the time) to 6×BEACOPP escalated and to 8×BEACOPP-14 (dose-dense 14-day cycle schedule).
Interventions and follow up
Arm A: 8×BEACOPP escalated — bleomycin 10mg/m² + etoposide 200mg/m² + doxorubicin 35mg/m² + cyclophosphamide 1250mg/m² + vincristine 1.4mg/m² + procarbazine 100mg/m²/d × 7d + prednisone 40mg/m²/d × 14d, q21d × 8 cycles
Arm B: 6×BEACOPP escalated (same doses, 6 cycles)
Arm C: 8×BEACOPP-14 (standard doses, accelerated 14-day schedule, mandatory G-CSF) × 8 cycles
Primary endpoint: Freedom from treatment failure (FFTF)
Median follow up: 67 months
Arm B: 6×BEACOPP escalated (same doses, 6 cycles)
Arm C: 8×BEACOPP-14 (standard doses, accelerated 14-day schedule, mandatory G-CSF) × 8 cycles
Primary endpoint: Freedom from treatment failure (FFTF)
Median follow up: 67 months
Results
5-year FFTF: 84.4% (8×eBEACOPP) vs 89.3% (6×eBEACOPP) vs 85.4% (8×BEACOPP-14)
6×eBEACOPP vs 8×eBEACOPP: superior FFTF (difference 4.9%, 95% CI 1.9–7.9)
5-year OS: 91.9% vs 95.3% vs 94.5% — 6×eBEACOPP superior to 8×eBEACOPP
PET-guided RT: only PET-positive residual masses ≥2.5cm received RT; RT required in 11% (vs ~60% in prior HD9 era)
6×eBEACOPP vs 8×eBEACOPP: superior FFTF (difference 4.9%, 95% CI 1.9–7.9)
5-year OS: 91.9% vs 95.3% vs 94.5% — 6×eBEACOPP superior to 8×eBEACOPP
PET-guided RT: only PET-positive residual masses ≥2.5cm received RT; RT required in 11% (vs ~60% in prior HD9 era)
Adverse events
Hematologic: Grade ≥3 leukopenia ~90% all arms; grade ≥3 anemia ~40–50%; febrile neutropenia ~20–30%
Serious/late: Treatment-related mortality 0.8–1.5%; secondary AML/MDS 0.6–1.0%; bleomycin grade ≥3 pulmonary toxicity ~2%
Serious/late: Treatment-related mortality 0.8–1.5%; secondary AML/MDS 0.6–1.0%; bleomycin grade ≥3 pulmonary toxicity ~2%
Conclusions
6×BEACOPP escalated was non-inferior to 8×BEACOPP escalated in FFTF with superior OS, establishing 6×eBEACOPP as the new GHSG standard for advanced cHL. BEACOPP-14 was inferior to both eBEACOPP regimens. PET-guided RT (only for PET-positive residuals ≥2.5cm) substantially reduced RT exposure.
Key Limitations
The non-inferiority margin interpretation is complex — HD15 tested equality rather than traditional non-inferiority. BEACOPP-14 was inferior, contrary to the hypothesis that dose-dense scheduling would match escalated dosing. Consolidative RT in PET-positive patients (11%) was still required, though HD18 later refined PET-adapted RT omission. Long-term toxicity including secondary malignancies and cardiovascular events favors de-escalation strategies explored in HD18 and HD21.
Clinical Context
HD15 shifted the GHSG standard from 8×eBEACOPP to 6×eBEACOPP, reducing cumulative chemotherapy exposure while maintaining efficacy. This was further built upon by HD18 (PET-adapted, 4×eBEACOPP for PET-negative patients) and HD21 (BrECADD, now preferred over eBEACOPP). In North America, ASCO-aligned practice favors ABVD-based therapy and ECHELON-1 (A+AVD); eBEACOPP use is more limited due to higher acute toxicity.